The effect of diet pill for weight loss therapies in obese patients

• Main Authors: Jhih-wei Wu, 吳芝瑋
• Other Authors: Tien-lung Tsai
• Format: Others
• Language: zh-TW
• Online Access: http://ndltd.ncl.edu.tw/handle/bds8r5

碩士 === 國立屏東教育大學 === 應用數學系 === 97 === The purpose of this study is to investigate the effect of Xenical for weight loss therapies on body weight, body mass index, blood pressure, and blood biochemical influence, and to examine the risk factor of metabolic disorder whether the improvement. The research results indicate that, by analysis of covariance and regression analysis, after 12 weeks of therapies, Xenical treatment causes a greater improvement then placebo treatment on body weight, body mass index, total cholesterol, high density lipoprotein, low density lipoprotein, and glutamyl transpeptidase, then the treatments and the baseline of plateles, glucose, alkaline phosphatase, total bilirubin, albumin, and ferritin interact. After 24 weeks of therapies, Xenical group causes a greater improvement then placebo treatment on body weight, body mass index, total cholesterol, low density lipoprotein density lipoprotein, then the treatments and the baseline of glucose, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, alkaline phosphatase, triglyceride and thyroid stimulating hormone interact. By contingency table analysis, abnormal proportions of all variables for obese patients on the first week and the 12th week are not significantly different between the two treatments. After 12 weeks of therapies, only the proportions of three changes for total cholesterol are significantly different between the two treatments. Abnormal proportions of hemoglobin and total cholesterol for obese patients on 24th week are significantly different between the two treatments, abnormal proportion of Xenical treatment is significantly lower than placebo treatment. After 24 weeks of therapies, the proportions of three changes for all variables are not significantly different between the two treatments. After 12 and 24 weeks of therapies, the proportions of the better on Xenical treatment for body mass index, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, and low density lipoprotein are more than the proportions of the worse, the proportions of the better on placebo treatment for body mass index, serum glutamic oxaloacetic transaminase, and triglyceride are more than the proportions of the worse, but the proportions of the worse for hemotocrit on 12 weeks and ferritin on 24 weeks are more than the proportions of the better. By logistic regression analysis, treatment does not influence significantly abnormal of all variables on the 12th week. Then, treatment influence significantly abnormal of total cholesterol on the 24th week, abnormal proportion of Xenical treatment for total cholesterol is significantly lower than placebo treatment’s. The abnormal proportions of all indicators of the metabolic syndrome between the two groups are not significantly different on the first, 12th, 24th weeks. After 12 and 24 weeks of therapies, the proportions of three changes for all indicators of the metabolic syndrome are not significantly different between the two treatments. After 12 weeks of therapies, the proportions of the better on Xenical and placebo treatments for body mass index and triglyceride are more than the proportions of the worse. After 24 weeks of therapies, the proportions of the better on Xenical treatment for body mass index, triglyceride, high density lipoprotein, glucose, and metabolic disorder are more than the proportions of the worse, the proportions of the better on placebo treatment for body mass index, triglyceride, high density lipoprotein, and metabolic disorder are more than the proportions of the worse. By logistic regression analysis, treatment does not influence significantly abnormal of all indicators of the metabolic syndrome on the 12th week. Then, treatment influence significantly abnormal of glucose on the 24th week, abnormal proportion of Xenical treatment for glucose is significantly lower than placebo treatment’s.